Trial Profile
A Phase I Surrogate Endpoint Trial of SU6668 in Patients With Incurable Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Nov 2011
Price :
$35
*
At a glance
- Drugs Orantinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 07 Sep 2006 Status change
- 27 Sep 2005 New trial record.